FOMX - フォ―ミックス・ファ―マシュ―ティカルズ (Foamix Pharmaceuticals Ltd.) フォ―ミックス・ファ―マシュ―ティカルズ

 FOMXのチャート


 FOMXの企業情報

symbol FOMx
会社名 Foamix Pharmaceuticals Ltd. (フォ―ミックス・ファ―マシュ―ティカルズ)
分野(sector) Consumer Durables   耐久消費財
産業(industry) Specialty Chemicals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations using its technology which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne rosacea and other skin conditions. Its product candidates include FMX101 FMX102 FMX103 and FDX104. Its lead product candidate FMX101 is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101 FMX102 FMX103 and FDX104.   フォ―ミックス・ファ―マシュ―ティカルズは、イスラエルの特殊医薬品会社。にきび、膿痂疹および他の皮膚疾患の治療用にミノサイクリンフォ―ムの開発、商品化を手掛ける。製品候補として、ミノサイクリンフォ―ム4%配合の中等度から重度のにきび用FMX101、ミノサイクリンフォ―ム1%配合の膿痂疹用FMX102の開発を行う。  Foamix Pharmaceuticals Ltd is a clinical-stage specialty pharmaceutical company. It is engaged in developing and commercializing minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. Its products include FMX101 & FMX103.
本社所在地 2 Holzman St. Weizmann Science Park Rehovot 7670402 ISR
代表者氏名
代表者役職名
電話番号 +972 8-931-6233
設立年月日 37622
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 75人
url www.foamix.co.il
nasdaq_url https://www.nasdaq.com/symbol/fomx
adr_tso
EBITDA EBITDA(百万ドル) -78.66200
終値(lastsale) 4.98
時価総額(marketcap) 203330033.52
時価総額 時価総額(百万ドル) 269.84650
売上高 売上高(百万ドル) 3.81400
企業価値(EV) 企業価値(EV)(百万ドル) 215.68150
当期純利益 当期純利益(百万ドル) -79.54900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Foamix Pharmaceuticals Ltd revenues increased 8% to $1.9M. Net loss increased 45% to $44.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 49% to $39.7M (expense) Selling general and administrative increase of 7% to $6.7M (expense) Financial Expense.

 FOMXのテクニカル分析


 FOMXのニュース

   Foamix Pharmaceuticals Ltd. (FOMX) CEO David Domzalski on Q1 2019 Results - Earnings Call Transcript  2019-05-08
Foamix Pharmaceuticals Ltd. (FOMX) Q1 2019 Earnings Conference Call May 08, 2019 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dave Domzalski - Chief Executive Officer Ilan Hadar - Chief Financial Officer & Country Manager Matt Wiley - Chief Commercial Of…
   Foamix Pharmaceuticals Ltd. (FOMX) CEO David Domzalski on Q1 2019 Results - Earnings Call Transcript  2019-05-08
Foamix Pharmaceuticals Ltd. (FOMX) Q1 2019 Earnings Conference Call May 08, 2019 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dave Domzalski - Chief Executive Officer Ilan Hadar - Chief Financial Officer & Country Manager Matt Wiley - Chief Commercial Of…
   Foamix Pharmaceuticals Ltd. (FOMX) CEO David Domzalski on Q1 2019 Results - Earnings Call Transcript  2019-05-08
Foamix Pharmaceuticals Ltd. (FOMX) Q1 2019 Earnings Conference Call May 08, 2019 08:30 AM ET Company Participants Michael Wood - LifeSci Advisors Dave Domzalski - Chief Executive Officer Ilan Hadar - Chief Financial Officer & Country Manager Matt Wiley - Chief Commercial Of…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 フォ―ミックス・ファ―マシュ―ティカルズ FOMX Foamix Pharmaceuticals Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)